Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05313009 2025-12-16

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Phase 1/2 Terminated

5 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06249282 2025-06-17

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Recruiting

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05631249 2025-05-08

CODEBREAK-IGR

Phase 2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05398094 2025-04-10

MERIT-lung

Phase 2 Recruiting

19 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT06314763 2024-04-30

ROSIE

Phase 4 Completed

21 enrolled

Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Venous Thromboembolism

NCT05311709 2023-11-09

SOLUCOM

Phase 2 Unknown

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05400577 2023-07-17

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05451056 2022-07-11

breakthrough

Phase 2 Unknown

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

CODEBREAK-IGR

MERIT-lung

EROS

ROSIE

SOLUCOM

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

breakthrough